Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial

  • Bayer AG BAYRY said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical study.
  • Nubeqa (darolutamide) improved overall survival in combination with standard care compared to standard care alone, which was the trial's primary goal.
  • The overall incidence of reported adverse events during the Phase 3 trial was similar between treatment arms.
  • Bayer will file the data with regulatory authorities to seek an expansion of the label for Nubeqa, which developed Nubeqa in collaboration with Finland's Orion.
  • Darolutamide is approved in multiple markets worldwide for non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.
  • Price Action: BAYRY shares are down 2.11% at $12.52 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 3 Trialprostate cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!